These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 24510538)

  • 1. Gene therapy of lung adenocarcinoma using herpes virus expressing a fusogenic membrane glycoprotein.
    Zhu B; Yang JR; Jiang YQ; Chen SF; Fu XP
    Cell Biochem Biophys; 2014 Jul; 69(3):583-7. PubMed ID: 24510538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tumor effects of gene therapy with GALV membrane fusion glycoprotein in lung adenocarcinoma.
    Zhu B; Yang JR; Fu XP; Jiang YQ
    Cell Biochem Biophys; 2014 Jul; 69(3):577-82. PubMed ID: 24519667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The construction of recombinant type I herpes simplex virus carrying GALV.fus gene and its antitumor effect in nude mice].
    Zhu M; Yang JR; Jiang YQ; Chen SF; Fu XP; Tian ZD
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Mar; 42(2):152-6. PubMed ID: 21500543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Packaging, amplification, and appraisal of the recombinant tumor-selective type I herpes simplex virus carrying GALV.fus gene.
    Bing Z; Jianru Y; Yuequan J; Shifeng C; Xinping F
    Cell Biochem Biophys; 2014 Sep; 70(1):321-6. PubMed ID: 24687598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect.
    Fu X; Tao L; Jin A; Vile R; Brenner MK; Zhang X
    Mol Ther; 2003 Jun; 7(6):748-54. PubMed ID: 12788648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
    Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
    J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas.
    Galanis E; Bateman A; Johnson K; Diaz RM; James CD; Vile R; Russell SJ
    Hum Gene Ther; 2001 May; 12(7):811-21. PubMed ID: 11339897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene therapy for malignant glioma using Sindbis vectors expressing a fusogenic membrane glycoprotein.
    Zhang J; Frolov I; Russell SJ
    J Gene Med; 2004 Oct; 6(10):1082-91. PubMed ID: 15368589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Syncytia formation affects the yield and cytotoxicity of an adenovirus expressing a fusogenic glycoprotein at a late stage of replication.
    Guedan S; Gros A; Cascallo M; Vile R; Mercade E; Alemany R
    Gene Ther; 2008 Sep; 15(17):1240-5. PubMed ID: 18509378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene therapy for acute myeloid leukemia using Sindbis vectors expressing a fusogenic membrane glycoprotein.
    Tan L; Xu B; Liu R; Liu H; Tan H; Huang W
    Cancer Biol Ther; 2010 Mar; 9(5):350-7. PubMed ID: 20061812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fusogenic membrane glycoproteins induce syncytia formation and death in vitro and in vivo: a potential therapy agent for lung cancer.
    Lin EH; Salon C; Brambilla E; Lavillette D; Szecsi J; Cosset FL; Coll JL
    Cancer Gene Ther; 2010 Apr; 17(4):256-65. PubMed ID: 19893593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A hyperfusogenic gibbon ape leukemia envelope glycoprotein: targeting of a cytotoxic gene by ligand display.
    Fielding AK; Chapel-Fernandes S; Chadwick MP; Bullough FJ; Cosset FL; Russell SJ
    Hum Gene Ther; 2000 Apr; 11(6):817-26. PubMed ID: 10779159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas.
    Allen C; McDonald C; Giannini C; Peng KW; Rosales G; Russell SJ; Galanis E
    J Gene Med; 2004 Nov; 6(11):1216-27. PubMed ID: 15459967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction of a replication-competent retroviral vector for expression of the VSV-G envelope glycoprotein for cancer gene therapy.
    Jin SY; Jung YT
    Arch Virol; 2020 May; 165(5):1089-1097. PubMed ID: 32146506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control.
    Simpson GR; Han Z; Liu B; Wang Y; Campbell G; Coffin RS
    Cancer Res; 2006 May; 66(9):4835-42. PubMed ID: 16651439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [An experimental study on targeting suicide gene therapy for lung cancer with HSV-TK driven by hTERT promoter].
    Wang YP; Tang XJ; Zhou QH; Che GW; Chen XH; Zhu DX
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):701-5. PubMed ID: 19024294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolysis using herpes simplex virus type 1 engineered to express cytosine deaminase and a fusogenic glycoprotein for head and neck squamous cell carcinoma.
    Price DL; Lin SF; Han Z; Simpson G; Coffin RS; Wong J; Li S; Fong Y; Wong RJ
    Arch Otolaryngol Head Neck Surg; 2010 Feb; 136(2):151-8. PubMed ID: 20157061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active adenoviral vascular penetration by targeted formation of heterocellular endothelial-epithelial syncytia.
    Chen HH; Cawood R; El-Sherbini Y; Purdie L; Bazan-Peregrino M; Seymour LW; Carlisle RC
    Mol Ther; 2011 Jan; 19(1):67-75. PubMed ID: 20877345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction.
    Johnson KJ; Peng KW; Allen C; Russell SJ; Galanis E
    Gene Ther; 2003 May; 10(9):725-32. PubMed ID: 12704411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly efficient tumor transduction and antitumor efficacy in experimental human malignant mesothelioma using replicating gibbon ape leukemia virus.
    Kubo S; Takagi-Kimura M; Logg CR; Kasahara N
    Cancer Gene Ther; 2013 Dec; 20(12):671-7. PubMed ID: 24201868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.